Abstract library

189 results for "tyrosine kinase inhibitor".
#1758 Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer
Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Roberta Modica
#566 A Case Report of a Patient with Metastatic Cervical Paraganglioma Responding to the Tyrosine Kinase Inhibitor Sunitinib
Introduction: Paragangliomas are rare neuroendocrine neoplasms that arise from neural crest cells, and are associated with increased expression of angiogenic growth factors. There have been isolated case reports describing potential efficacy with Sunitinib, a tyrosine kinase inhibitor.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Olga Oikonomidou
#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)
Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maria Gueorguiev
#1739 A Kinomic Approach to Identify Signaling Proteins Involved in Drug Resistance in GastroEnteroPancreatic Neuroendocrine Tumors
Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) result in tumour growth stabilization, eventually followed by tumour progression. Thus, despite their original characteristics, NETs exhibit similar resistance features to treatments than other more common tumours.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr David Romano
#1039 Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET
Introduction: The main treatment for bronchopulmonary NET(BP-NET) is surgery, which is not feasible for infiltrating and metastatic disease, where medical therapy is tried. Identifying new therapeutic targets is important to provide adequate medical treatment for patients with BP-NET. Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI), is mainly described to inhibit VEGF
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Teresa Gagliano
Keywords: RTK, BP-NET, IGF1R, EGFR
#1111 Autophagy as a Possible Mechanism of Resistance in pNET Treatment
Introduction: Pancreatic neuroendocrine tumor (pNET) patients often display primary or secondary resistance to Sunitinib, an anti-angiogenic multi-receptor tyrosine kinase inhibitor which has been approved for the treatment of late stage pNETs. In late cancer stage autophagy often has a tumor promoting role. Sunitinib might additionally activate autophagy through inhibition of mTOR or induction of hypoxia.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tabea Wiedmer
#1737 The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer
Introduction: Upon diagnosis, 65% of pNET patients suffer from metastatic or locally unresectable disease. The receptor tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus have set precedence for successful targeted therapies in pNET disease. However, response prediction and treatment alternatives still do not meet medical needs. Recent studies revealed mutations in RAS oncogenes in a fraction of tumours, emphasising a potential role of the MAPK pathway as therapeutic target.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Julia Hoffmann
#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H, ...
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mónica Inês
Authors: Soares M, Inês M, Contente M, ...